The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of Zoetis Inc. (NYSE: ZTS) (“Zoetis”).

On April 12, 2024, The Wall Street Journal published an article on Zoetis reporting that health regulators in the U.S. and Europe have received thousands of complaints about Zoetis’s arthritis drugs, Librela (for dogs) and Solensia (for cats), due to negative side effects. Additionally, the article reported that U.S. and Europe health regulators are conducting reviews of the drugs.

Following this news, Zoetis’s stock price fell 8%, to close at $149.98 per share on April 12, 2024.

If you are a Zoetis investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ktmc.com. You can also click on the following link or paste it in your browser: https://www.ktmc.com/new-cases/zoetis-inc?utm_source=PR&utm_medium=link&utm_campaign=zts&mktm=r

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415367743/en/